Clinical trials: Plaque
Psoriasis, Plaque Type Psorisis
Evaluation of Safety and Efficacy of IRX4204 in Mild to Moderate Plaque Psoriasis
The goal of this clinical trial is to learn if IRX4204 works to treat plaque psoriasis in adults. It will also learn about the safety of IRX4204.
- Conditions
- Psoriasis, Plaque Type Psorisis, Plaque Psoriasis
- Trial name
- NCT06723171
- Testing
- IRX4204
- Where
- United States
- Volunteers
- 20 people
- Sponsor
- Io Therapeutics
Psoriasis
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
An Open-label, Single-dose Study to Evaluate Safety, Tolerability, and Pharmacokinetics of Brodalumab in Pediatric Subjects
- Trial name
- NCT03240809
- Testing
- Brodalumab
- Where
- 5 sites in United States
- Volunteers
- 2 people
- Sponsor
- Bausch Health Americas, Inc.
Psoriasis
Efficacy and Safety of HAT1 Compared to Calcipotriol in Patients With Mild to Moderate Chronic Plaque Psoriasis
Psoriasis, the most prevalent autoimmune disease in the U.S., manifests with plaque type psoriasis vulgaris with lesions localized to the scalp, postauricular region, face, diaper area, elbows, and knees.
- Trial name
- NCT03848806
- Testing
- HAT1, Calcipotriol
- Volunteers
- 174 people
- Sponsor
- Haus Bioceuticals
Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis
A Study With a Initial Treatment Period Followed by a Randomized-withdrawal Period to Evaluate the Efficacy and Safety of Bimekizumab in Adult Subjects With Moderate to Severe Chronic Plaque Psoriasis
Phase 3 study to compare the efficacy of bimekizumab versus placebo in the treatment of subjects with moderate to severe chronic plaque psoriasis.
- Conditions
- Chronic Plaque Psoriasis, Moderate to Severe Chronic Plaque Psoriasis, Psoriatic Arthritis
- Trial name
- BE READY (NCT03410992)
- Testing
- Bimekizumab
- Where
- 77 sites in United States, Australia and 7 more
- Volunteers
- 435 people
- Sponsor
- UCB Biopharma SRL
Psoriasis
An Efficacy and Safety of CNTO 1959 (Guselkumab) in Participants With Moderate to Severe Plaque-type Psoriasis
The purpose of this study is to demonstrate the superiority of CNTO 1959 (guselkumab) to placebo in the treatment of participants with moderate to severe plaque-type psoriasis (A common genetically determined, chronic…
- Trial name
- NCT02325219
- Testing
- CNTO 1959 50 mg, CTNO 1959 100 mg
- Where
- 27 sites in Japan
- Volunteers
- 192 people
- Sponsor
- Janssen Pharmaceutical K.K.
Psoriasis
A Study of the Safety and Efficacy of Ustekinumab (CNTO 1275) in Patients With Moderate to Severe Psoriasis
The primary objective of this study is to evaluate the efficacy and safety of ustekinumab (CNTO 1275) in the treatment of patients with moderate to severe plaque psoriasis.
- Trial name
- NCT00307437
- Testing
- Ustekinumab (CNTO 1275) 45 mg, Ustekinumab (CNTO 1275) 90 mg
- Where
- 62 sites in United States, Austria and 5 more
- Volunteers
- 1,230 people
- Sponsor
- Centocor Research & Development, Inc.
Psoriasis
A Dose Ranging Study to Evaluate the Safety and Efficacy of GSK2586184 in Patients With Chronic Plaque Psoriasis
A multi-centre, randomised, dose ranging study to evaluate the safety and clinical efficacy of GSK2586184 in patients with chronic plaque psoriasis. There will be 2 study cohorts (Cohorts A and B).
- Trial name
- NCT01782664
- Testing
- 100 mg GSK2586184, 200 mg GSK2586184, 400 mg GSK2586184
- Where
- 15 sites in Germany, United Kingdom
- Volunteers
- 68 people
- Sponsor
- GlaxoSmithKline
Oral Hygiene, Toothbrushing
Open-label Trial Evaluating Four Oral Hygiene Regimens Using a Manual Toothbrush, Toothpaste, and Mouthwash
The purpose of this open-label, randomized controlled clinical trial, is to provide preliminary clinical data (efficacy on plaque and gingival sensitivity, and safety and tolerability of two types of toothpaste, a mouthwash, and…
- Conditions
- Oral Hygiene, Toothbrushing, Dental Plaque
- Trial name
- NCT05999175
- Testing
- the toothpaste is used with a standard toothbrush without any claims 3 times a day after the main meals for 28 days., the mint toothpaste and mouthwash are used with the scalar toothbrush 33 medium with antibacterial " Spazzolino tau-marin®" 3 times a day after the main meals for 28 days., subjects of this group will use their routine oral hygiene products.
- Where
- 2 sites in Italy
- Volunteers
- 84 people, healthy volunteers welcome
- Sponsor
- Biokosmes Srl
Alzheimer's Disease
Dose-ranging Safety and Tolerability Study in Subjects ≥60 Years of Age
The study determined the safety of CNP520 in healthy elderly over 3 months. Data relevant for Pharmacokinetic/Pharmacodynamic modeling were obtained in order to define the target dose in subsequent efficacy studies.
- Trial name
- NCT02576639
- Testing
- CNP520
- Where
- 11 sites in United States, Belgium and 3 more
- Volunteers
- 124 people, healthy volunteers welcome
- Sponsor
- Novartis Pharmaceuticals
Plaque Psoriasis
BTT1023 in Psoriasis
Patients with plaque psoriasis will be enrolled. They will be dosed with repeated intravenous doses of BTT-1023 or placebo. During the trial, the safety of the treatments and the pharmacokinetics of BTT-1023 will be assessed.
- Trial name
- NCT00871598
- Testing
- BTT1023
- Where
- 5 sites in Germany
- Volunteers
- 26 people
- Sponsor
- Biotie Therapies Corp.
Psoriasis
Chronic Plaque Psoriasis Study With Topical Formulation Of GW786034
This study is an exploratory study to evaluate the effectiveness, safety and tolerability of three concentrations of GW786034 ointment following treatment to small areas of stable psoriatic plaques.
- Trial name
- NCT00358384
- Testing
- Pazopanib, Pazopanib vehicle, Betamethasone valerate
- Where
- France
- Volunteers
- 10 people
- Sponsor
- GlaxoSmithKline
Psoriasis
A Safety/Efficacy Study of a Non-steroid, Topical Cream Treatment of Psoriasis Over 12-weeks
Psoriasis is a chronic inflammatory skin disorder that is characterized by hyperproliferation of the keratinocytes and inflammation of the epidermal and dermal layers of the skin.
- Trial name
- 134993 (NCT01098721)
- Testing
- WBI-1001
- Volunteers
- 61 people, healthy volunteers welcome
- Sponsor
- Welichem Biotech Inc.
Plaque Psoriasis
A Single-Center Exploratory Study to Assess the Activity of CRx-197-002 in Plaque Psoriasis
This will be a phase 2a single-center, randomized, blinded, vehicle-controlled exploratory study to assess the activity and safety of CRx-197 in subjects with plaque psoriasis.
- Trial name
- 197-002 (NCT00796211)
- Testing
- CRx-197, Nortriptyline, Calcipotriol
- Where
- Germany
- Volunteers
- 20 people
- Sponsor
- Zalicus
Dental Plaque, Bleeding of Subgingival Space
Antibacterial Photodynamic Therapy as an Adjunctive Treatment on Oral Hygiene in Elderly Persons
On average, the dental condition of elderly people is poor due to various reasons. The importance of oral health maintenance of the ageing population has been recognized by the World Health Organization (WHO), as oral health…
- Conditions
- Dental Plaque, Bleeding of Subgingival Space, Oral Complication
- Trial name
- NCT06576063
- Testing
- Lumoral Treatment, Standard oral hygiene methods
- Where
- 3 sites in Finland
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Koite Health Oy
Psoriasis
Efficacy and Safety Study of CD 2027 Spray in Subjects With Plaque-type Psoriasis
This was a multicenter, randomized, vehicle-controlled, double-blind parallel group study to evaluate the efficacy and safety of CD 2027 Oily Spray applied twice daily for 8 weeks in participants with plaque-type psoriasis.
- Trial name
- NCT00763555
- Testing
- CD 2027, Calcitriol Vehicle
- Where
- 6 sites in United States, Canada
- Volunteers
- 88 people
- Sponsor
- Galderma R&D
Plaque Psoriasis, Psoriasis
Study to Evaluate the Efficacy and Safety of JTE-451 in Subjects With Moderate to Severe Plaque Psoriasis
Study to evaluate the efficacy and safety of JTE-451 administered for 16 weeks in subjects with moderate to severe plaque psoriasis.
- Conditions
- Plaque Psoriasis, Psoriasis, Skin Diseases
- Trial name
- IMPACT-PS (NCT03832738)
- Testing
- JTE-451 Tablets
- Where
- 33 sites in United States, Canada and 1 more
- Volunteers
- 152 people
- Sponsor
- Akros Pharma Inc.
Psoriasis
A Study to Evaluate the Benefit and Safety of GSK2982772 in Moderate to Severe Psoriasis Participants
Plaque psoriasis is a chronic relapsing inflammatory skin disease that is characterized by keratinocyte hyper-proliferation and epidermal hyperplasia.
- Trial name
- NCT04316585
- Testing
- GSK2982772
- Where
- 9 sites in Canada, Poland
- Volunteers
- 29 people
- Sponsor
- GlaxoSmithKline
Plaque Psoriasis
Study of Efficacy and Safety of Secukinumab 2 mL Auto-injector (300 mg) in Subjects With Moderate to Severe Plaque Psoriasis
The primary purpose of this study is to assess efficacy, safety and tolerability of a 2 mL pre-filled auto-injector (AI) of 300 mg secukinumab in patients with moderate to severe plaque psoriasis
- Trial name
- MATURE (NCT03589885)
- Testing
- Secukinumab 2 mL auto-injector, Secukinumab 1 mL prefilled syringe
- Where
- 22 sites in United States, Canada and 4 more
- Volunteers
- 122 people
- Sponsor
- Novartis Pharmaceuticals
Dental Plaque, Gingivitis
Clinical Study Comparing Dental Plaque and Gingivitis Reduction After Using One of Three Oral Hygiene Multi-component Regimens (Using of a Manual Toothbrush, a Toothpaste and a Mouthwash)
The objective of this clinical research study is to assess the efficacy of a commercially available triclosan/copolymer toothpaste compared to a commercially available oral hygiene multi-component regimen encompassing the use of…
- Trial name
- NCT02366689
- Testing
- Triclosan/fluoride toothpaste, stannous fluoride toothpaste, fluoride only toothpaste
- Where
- United States
- Volunteers
- 179 people, healthy volunteers welcome
- Sponsor
- Colgate Palmolive
Dental Plaque, Gingivitis
A Clinical Study to Evaluate the Efficacy of a Cetylpyridinium Chloride Mouthwash in Improving Gingival Health and Reducing Plaque Accumulation
The aim of this 12-week clinical study is to evaluate the ability of an experimental mouthwash, containing 0.085 percent (%) Cetylpyridinium chloride (CPC) as an adjunct to toothbrushing with a regular fluoride toothpaste, to…
- Trial name
- NCT06933368
- Testing
- Crest Cavity Protection Toothpaste, Experimental Mouthwash
- Where
- United States
- Volunteers
- 138 people, healthy volunteers welcome
- Sponsor
- HALEON